Cost-effectiveness analysis of oral antiviral therapy in patients with indeterminate chronic hepatitis B infection.

ABSTRACT:

Background

Compared to patients with chronic hepatitis B (CHB) in the immune tolerance phase, those in the indeterminate phase (IP) tend to have a higher proportion of liver inflammation and fibrosis, and they usually progress more rapidly to hepatocellular carcinoma (HCC). However, no definitive conclusion has been reached regarding the necessity of antiviral therapy (AVT) for patients in the IP. The present study aims to evaluate the cost-effectiveness of oral antiviral treatment in CHB patients who are in the IP [indeterminate phase-chronic hepatitis B (IP-CHB)] from a healthcare system perspective.

Methods

Cost and effectiveness, measured in quality-adjusted life years (QALYs), were compared in a virtual cohort of 100,000 CHB patients in the IP receiving AVT (scenario I)

SUBMITTER: Zhuo HY 

PROVIDER: S-EPMC12314709 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature